Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 20/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11898790 | 1.00 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL11899702 | 1.00 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL10090476 | 0.83 | GRIA2 (0.68) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL8213103 | 0.83 | GRIA2 (0.68) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL2935780 | 0.82 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL960432 | 0.82 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL585486 | 0.82 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL585485 | 0.82 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL8158583 | 0.82 | GRIA2 (0.59) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL7890493 | 0.81 | GRIA2 (0.56) | GRIA2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-8173820-B2 | Compounds which potentiate the AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173820-B2 | Compounds which potentiate the AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| CN-102365265-A | Indane derivatives | ORGANON NV | 2012-02-29 | — | — | CN | disclosed |
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2222632-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | Glaxo Group Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010037760-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009080637-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080637-A1 | COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021578-A1 | Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM1, GRM2 | GRIA2 20/4885CYP1A2 1001/4885CYP2C19 949/4885 |
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | GRIA2 24/4885CYP1A2 717/4885CYP2C19 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.